Back to results
US 8,410,049 B2Granted
Methods and kits for preventing hypoglycemia
AssigneeCebix AB
InventorsJohn Wahren, Karin Ekberg, James Callaway
Life of this patent
Estimating the term…
Abstract
Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.
Claims24
A method for treating an insulin-dependent human patient, comprising the steps of:
- a. administering insulin to said patient, wherein said patient has neuropathy;
- b. administering subcutaneously to said patient a therapeutic dose of pegylated C-peptide in a different site as that used for said patient's insulin administration;
- and
- c. adjusting the dosage amount, type, or frequency of insulin administered based on monitoring said patient's altered insulin requirements resulting from said therapeutic dose of pegylated C-peptide, wherein said adjusted dose of insulin reduces the risk, incidence, or severity of hypoglycemia, wherein said adjusted dose of insulin is at least 10% less than said patient's insulin dose prior to starting pegylated C-peptide treatment.
1 more element
A method of reducing insulin usage in an insulin-dependent human patient, comprising the steps of;:
- a. administering insulin to said patient, wherein said patient has neuropathy;
- b. administering subcutaneously to said patient a therapeutic dose of pegylated C-peptide in a different site as that used for said patient's insulin administration;
- and
- c. adjusting the dosage amount, type, or frequency of insulin administered based on monitoring said patient's altered insulin requirements resulting from said therapeutic dose of pegylated C-peptide, wherein said adjusted dose of insulin does not induce hypoglycemia, wherein said adjusted dose of insulin is at least 10% less than said patient's insulin dose prior to starting pegylated C-peptide treatment.
1 more element
Dependencies are inferred from the claim text.